Armephaco JSC

Armephaco JSC Financing Cash Flow

The Net Financing Cash Flow of Armephaco JSC (AMP.VN) as of Oct 30, 2026 is 35.78 B VND. In the previous year, Net Financing Cash Flow was -5.65 B VND — a change of -733.54% (higher).

Financing Cash Flow

35.78 BVND

YoY

-733.54%

Last updated:

Net Financing Cash Flow of Armephaco JSC is 2024 35.78 B VND. Net Financing Cash Flow of Armephaco JSC was 2023 -5.65 B VND. It decreases by -733.54% higher compared to the previous year.

The Armephaco JSC Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
-7.50 B VND
Jan 1, 2018
8.09 B VND
Jan 1, 2019
-19.25 B VND
Jan 1, 2020
17.77 B VND
Jan 1, 2021
-34.38 B VND
Jan 1, 2022
-37.76 B VND
Jan 1, 2023
-5.65 B VND
Jan 1, 2024
35.78 B VND
The Armephaco JSC Financing Cash Flow history
YEARFinancing Cash FlowYoY
35.78 BVND-733.54%
-5.65 BVND-85.04%
-37.76 BVND+9.84%
-34.38 BVND-293.47%
17.77 BVND-192.34%
-19.25 BVND-338.05%
8.09 BVND-207.76%
-7.50 BVND-107.32%
102.52 BVND+52.30%
67.31 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Armephaco JSC Stock analysis

What does Armephaco JSC do? Armephaco JSC manufactures pharmaceutical and medical equipment products, focusing on glucose meters, sphygmomanometers, beds, medical exam tables, stools, and syringe destroyers. The company distributes medical devices and equipment through its manufacturing and distribution channels, targeting healthcare providers and hospitals. It also produces and trades diversified medicines, including antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs, serving the broader healthcare market. The firm generates revenue from the sale of medical devices and equipment, as well as from pharmaceutical products. Healthcare providers and hospitals purchase the medical devices and equipment, while the diversified medicines are sold to pharmacies and healthcare institutions. Armephaco JSC's product portfolio includes glucose meters, sphygmomanometers, beds, medical exam tables, stools, syringe destroyers, antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs. Armephaco JSC's business model centers on the production and distribution of medical devices and pharmaceuticals. The company's primary customers are healthcare providers, hospitals, pharmacies, and healthcare institutions. The revenue streams are derived from the direct sale of medical equipment and pharmaceutical products to these segments, with no mention of additional services or partnerships. Armephaco JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Armephaco JSC stock

Net Financing Cash Flow of Armephaco JSC is 35.78 B VND in 2024.

Net Financing Cash Flow of Armephaco JSC changed from -5.65 B VND to 35.78 B VND, representing a -733.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Armephaco JSC since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Armephaco JSC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Armephaco JSC

All Key Metrics — Armephaco JSC